ELISpot (Drug Discovery) Reference

[1] Mollenkopf HJ, et al., Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis, Infect Immun, 2004, 72(11):6471-9;

[2] van Pel M, et al., Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers, Bone Marrow Transplant, 2003, 32(1):15-22.

The B cell ELISpot assay is central to the characterization of adaptive immune responses to infection, immune modulators, vaccines and therapeutic agents.

Combined with computational predictions, IFN-γ ELISpot is well applied in identification of novel DNA vaccine candidates. [1]

Together with skin transplantation, IFN-γ ELISpot was utilized to prove that treosulfan is a better candidate for conditioning to induce donor-specific allograft tolerance than other myeloablative regimens (eg irradiation or busulfan admin- istration) for its lower nonhematological toxicity.